Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
ISIN : CNE1000000W4
Share Class Description:
FRA:FDY: Class HTotal Employee Number:
876Compare
Compare
Traded in other countries / regions
01349.Hong Kong688505.ChinaFDY.Germany IPO Date
2020-11-02Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. The company has launched it's four types of photodynamic drugs in China market, namely hematoporphyrin, aminolevulinic acid hydrochloride, Verteporfin and Hemoporfin. Geographically, it derives revenue from Mainland China.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 78.08 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 13.53 | |||||
Beneish M-Score | -3.64 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.2 | |||||
3-Year FCF Growth Rate | 11.4 | |||||
3-Year Book Growth Rate | -2.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.25 | |||||
9-Day RSI | 50.7 | |||||
14-Day RSI | 47.64 | |||||
3-1 Month Momentum % | -17.42 | |||||
6-1 Month Momentum % | -15.23 | |||||
12-1 Month Momentum % | -26.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.05 | |||||
Quick Ratio | 5.91 | |||||
Cash Ratio | 4.67 | |||||
Days Inventory | 445.93 | |||||
Days Sales Outstanding | 344.97 | |||||
Days Payable | 90.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.38 | |||||
3-Year Dividend Growth Rate | -26.9 | |||||
Forward Dividend Yield % | 2.39 | |||||
5-Year Yield-on-Cost % | 0.86 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | 1.39 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.01 | |||||
Operating Margin % | -49.55 | |||||
Net Margin % | -55.42 | |||||
EBITDA Margin % | -32.72 | |||||
FCF Margin % | 10.58 | |||||
OCF Margin % | 30.79 | |||||
ROE % | -7.38 | |||||
ROA % | -6.62 | |||||
ROIC % | -12.58 | |||||
3-Year ROIIC % | 319.46 | |||||
ROC (Joel Greenblatt) % | -26.99 | |||||
ROCE % | -7.19 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 16.85 | |||||
PS Ratio | 7.22 | |||||
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.06 | |||||
Price-to-Free-Cash-Flow | 68.48 | |||||
Price-to-Operating-Cash-Flow | 24.84 | |||||
EV-to-EBIT | -30.79 | |||||
EV-to-EBITDA | -51.51 | |||||
EV-to-Revenue | 16.85 | |||||
EV-to-FCF | 147.45 | |||||
Price-to-GF-Value | 1.06 | |||||
Price-to-Projected-FCF | 1.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.81 | |||||
| Price-to-Net-Cash | 2.54 | |||||
Earnings Yield (Greenblatt) % | -3.25 | |||||
FCF Yield % | 0.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 35.59 | ||
| EPS (TTM) (€) | -0.02 | ||
| Beta | 0.5068 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.13 | ||
| Volatility % | 38.98 | ||
| 14-Day RSI | 47.64 | ||
| 14-Day ATR (€) | 0.005451 | ||
| 20-Day SMA (€) | 0.2482 | ||
| 12-1 Month Momentum % | -26.86 | ||
| 52-Week Range (€) | 0.234 - 0.484 | ||
| Shares Outstanding (Mil) | 1,043 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| HKD 0.032100 Cash Dividend | 2025-07-10 | 0.37 (+0.00%) | ||
| HKD 0.021700 Cash Dividend | 2024-08-26 | 0.20 (+0.00%) | ||
| HKD 0.075700 Cash Dividend | 2024-07-04 | 0.20 (+0.00%) |
Show
Entries
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY)'s stock price today?
The current price of FRA:FDY is €0.25. The 52 week high of FRA:FDY is €0.48 and 52 week low is €0.23.
When is next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY)?
The next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY) is .
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY) is 1.38% (As of Today), Highest Dividend Payout Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY) was 8.73. The lowest was 0.21. And the median was 0.55. The  Forward Dividend Yield % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(FRA:FDY) is 2.39%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers